Molecular Targeting Technologies, Inc.

West Chester,  PA 
United States
http://www.mtarget.com

• Booth: 1819

MTTI is a clinical stage company transforming the lives of patients with severe diseases thru innovative targeted theranostics.

EBTATE (177Lu-EB-DOTA-TATE) radiotherapeutic targets somatostatin receptors in neuroendocrine neoplasms​.  EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing PRRTs. EBTATE trials in 62   NET patients were well tolerated and more effective than 177Lu-DOTA-TATE at 40% of the radioactivity dosed.   3-year follow up showed 86% disease control.    Trials expanding into small cell lung , Hurthle cell thyroid and nasopharyngeal cancers. Ac225 homolog in development.  Acquired under an exclusive global license from NIH.

EBRGD (177Lu-EB-DOTA-RGD) is a selective, cancer fighting radiotherapeutic targeting αvβ3-expressing tumors. Studies are currently focused on non-small cell lung cancer and glioblastoma multiforme.  Acquired under an exclusive global license from NIH.

TDURA (99mTc-duramycin) radiodiagnostic targets PE, externalized in dying cells.  Clinical trials imaging colorectal tumor response to chemotherapy underway.

FGA (18F-fluoroglucaric acid) radiodiagnostic targets histones to detect necrosis and apoptosis, tracking tumor response to therapy.  MTTI owns a proprietary, low cost route from FDG.  FGA holds promise in a range of diseases. 

Our Team: Seasoned executives from multinational pharmaceutical companies, each with a successful track record.

Brands: EBTATE (177Lu-EB-DOTA-TATE) EBRGD (177Lu-EB-DOTA-RGD) TDURA (99mTc-duramycin) FGA (18F-fluoroglucaric acid)

 Press Releases

• MTTI reports on 225Ac-EBTATE radiopharmaceutical at 2024 Society of Nuclear Medicine and Molecular Imaging annual meeting (May 28, 2024)

  West Chester, PA, May 21, 2024 -- Molecular Targeting Technologies, Inc. (MTTI), will update findings on both ¹⁷⁷Lu-EBTATE clinical and ²²⁵Ac-EBTATE preclinical work during the 2024 SNMMI meeting in Toronto Convention Center (exhibition booth #1819)

  EBTATE®, an EvaThera platform therapeutic, is the first patented long-acting peptide targeted radiotherapeutic drug. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide payload. Evans blue (EB) in EBTATE binds to serum albumin, extending in vivo circulatory half-life and tumor residence time, enabling effective use of significantly lower radiopharmaceutical activity and fewer dosing cycles vs. the current standard of care.

  Professor Zhaohui Zhu, MD, Peking Union Medical College Hospital, said “Our 3-year follow up in patients* (N=30) with metastatic neuroendocrine tumors, ¹⁷⁷Lu-EBTATE demonstrated good safety with no nephro- or hepatoxicity and 86% disease control rate using 60% less radioactivity than ¹⁷⁷Lu-DOTATATE. We observed low incidence of grade 3 hematoxicity (3.4% vs 15% of reported SOC) and no nephrotoxicity of any grade in long-term safety evaluation.”

  The study “Long acting ²²⁵Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive small-cell lung cancer**” has been accepted for presentation on June 8, 2024, at the SNMMI. Professor Humphrey Fonge, Ph.D. of the University of Saskatchewan commented, "We demonstrated that ²²⁵Ac-EBTATE (2x 30 kBq administered 10 days apart) was effective against human small-cell lung cancer (SCLC) with 80% complete remissions and 100% survival. It presented a 2-fold greater tumor growth inhibition (%TGI) compared with ²²⁵Ac-DOTATATE, at 60% less radioactivity administered. Toxicity, as measured by body weight, blood counts, and chemistry showed that ²²⁵Ac-EBTATE was well tolerated at a highly effective dose. ²²⁵Ac-EBTATE shows great promise against SCLC".

  Chris Pak, President & CEO of MTTI commented: “It is encouraging to see how EBTATE helped these patients as well as the exciting findings of ²²⁵Ac-EBTATE.  We look forward to the same benefits from EBTATE trials in small-cell lung cancer, nasopharyngeal cancers, Hürthle cell thyroid and others.”

  Molecular Targeting Technologies, Inc. (MTTI). Molecular Targeting Technologies, Inc. is a private, clinical stage biotech developing targeted radiotherapeutics for rare cancers. MTTI is committed to building value by translating innovative radiopharmaceuticals to improve human health. For more information: www.mtarget.com; www.evathera.com 

  Contact: Chris Pak, Email: cpak@mtarget.com

  *Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics 2022; 12: 6437-6445 

  **The data will be presented in Session MTA02 POPs/Meet the Author: Oncology, Basic and Translational 1, Saturday, June 8, 2024, 3:30 PM - 4:45 PM.  It is co-authored by Fabrice N. Njotu, Humphrey Fonge et al. of the University of Saskatchewan, and Molecular Targeting Technologies, Inc.